Patient Information

MS affects more than 1.2 million people worldwide, including 600,000 people in Europe. Spasticity is one of the most common and most disabling symptoms of MS, affecting up to 84% of patients.

It is widely recognised that currently available treatments are inadequate. Sativex has been developed as a treatment for the relief of symptoms in patients with moderate to severe spasticity that have not been adequately treated with currently used therapies. It is able to relieve spasticity, reduce spasms, improve sleep and improve function.

Please find patient information regarding Sativex and MS spasticity below:

For more relevant information on the most common symptoms of Multiple Sclerosis (MS), as well as its causes, signs, incidence and available treatments, please visit http://www.lifeandms.com/

Sativex is now marketed as a treatment for MS spasticity in the UK, Germany, Spain and Denmark. Sativex has also been approved/recommended for approval in a further 14 European countries. Launches are expected in these markets during 2012-13. These countries are Italy, Sweden, Austria, Czech Republic, Belgium, Finland, Iceland, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal and Slovakia.

Global Expansion

Beyond Europe, approval has already been granted in Canada, Israel and New Zealand. Regulatory applications are underway/being prepared in selected countries in the Middle East and Asia.